Q2i is a Digital Health Company

dedicated to developing, refining, validating, and commercializing innovative, evidence-based solutions.

Q2i’s technology is developed with the support of, and in conjunction with:


Project Title	Date started	Status	Academic Partner/s
Buprenorphine induction low-dose to depot (build2depot): development of safe rapid transfer to depot medication and go/no go testing potential of remote community-based monitoring.	2024	In recruitment phase
Prison release engagement trial, smartphone app to improve continuity of care post release for released prisoners (RPS) who want to stay drugfree	2024	In recruitment phase
PARCA (a digital tool) to improve justice and health	2023	Phase I STTR successfully completed, and now in Phase II (Dallas and Austin)
Digital health technology improving successful community reintegration of recently released justice involved individuals with substance use disorders	2020	Phase I STTR successfully completed results published
Reward-Based technology to improve opioid use disorder treatment after an ED visit	2019	Phase I and Phase II STTR successfully completed Completed in data analysis phase
Technology improving the success of medication assisted treatment in primary care	2019	Phase I and Phase II STTR successfully completed Manuscript drafted ready for peer review